Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRK-001 + tacrolimus is a combination drug consisting of TRK-001 and tacrolimus. Tacrolimus is a small-molecule immunosuppressant, specifically a calcineurin inhibitor, used primarily to prevent organ transplant rejection. It inhibits T-cell activation by binding to FKBP-12, forming a complex that inhibits calcineurin phosphatase activity, resulting in reduced transcription of interleukin-2 and other cytokines and blocking the progression of T cells from the G0 to G1 phase[3][4][1]. No definitive information is available in the provided data regarding TRK-001’s mechanism, structure, or clinical indications when used in combination with tacrolimus. As a result, the description is limited to the known properties of tacrolimus and the structure of the combination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TRK-001 + tacrolimus.